德国920家医院10021例COVID-19住院患者的特征、资源使用与结局
结果显示1727例(17%)接受机械通气,院内总死亡率为22%,通气患者死亡率达53%。结论认为在医疗系统未被挤兑的情况下,机械通气患者死亡率仍较高,80岁及以上及需透析者尤甚。
要点
- 住院COVID-19患者机械通气比例为17%,通气患者院内死亡率为53%。
- 院内总死亡率为22%,未通气患者为16%,通气患者为53%。
- 通气且需透析者院内死亡率达73%,80岁及以上通气患者为72%。
核心结论
- 在德国医疗系统未被COVID-19疫情挤兑的背景下,接受机械通气的患者院内死亡率较高,尤其是80岁及以上患者和需要透析的患者,而60岁以下患者死亡率明显较低。
研究设计与样本
- 观察性研究,分析德国地方医保基金索赔数据。
- 纳入2020年2月26日至4月19日在德国住院、确诊COVID-19且住院过程完整的成人患者。
主要发现
- 患者中位年龄72岁(IQR 57-82)。
- 女性通气比例为12%(580/4822),男性为22%(1147/5199)。
- 最常见合并症为高血压5575例(56%)、糖尿病2791例(28%)、心律失常2699例(27%)。
关键数值与推荐
- 通气患者中,仅无创通气者死亡65/145(45%),无创通气失败者死亡70/141(50%),有创机械通气者死亡696/1318(53%)。
- 全部患者中需透析者599例(6%),通气患者中需透析者469例(27%)。
- 通气且需透析者院内死亡率为73%(342/469)。
- 通气患者院内死亡率按年龄从18-59岁的28%(117/422)到80岁及以上的72%(280/388)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Background Nationwide, unbiased, and unselected data of hospitalised patients with COVID-19 are scarce. Our aim was to provide a detailed account of case characteristics, resource use, and outcomes of hospitalised patients with COVID-19 in Germany, where the health-care system has not been overwhelmed by the pandemic. METHODS: In this observational study, adult patients with a confirmed COVID-19 diagnosis, who were admitted to hospital in Germany between Feb 26 and April 19, 2020, and for whom a complete hospital course was available (ie, the patient was discharged or died in hospital) were included in the study cohort. Claims data from the German Local Health Care Funds were analysed. The data set included detailed information on patient characteristics, duration of hospital stay, type and duration of ventilation, and survival status. Patients with adjacent completed hospital stays were grouped into one case. Patients were grouped according to whether or not they had received any form of mechanical ventilation. To account for comorbidities, we used the Charlson comorbidity index. FINDINGS: Of 10 021 hospitalised patients being treated in 920 different hospitals, 1727 (17%) received mechanical ventilation (of whom 422 [24%] were aged 18-59 years, 382 [22%] were aged 60-69 years, 535 [31%] were aged 70-79 years, and 388 [23%] were aged ≥80 years). The median age was 72 years (IQR 57-82). Men and women were equally represented in the non-ventilated group, whereas twice as many men than women were in the ventilated group. The likelihood of being ventilated was 12% for women (580 of 4822) and 22% for men (1147 of 5199). The most common comorbidities were hypertension (5575 [56%] of 10 021), diabetes (2791 [28%]), cardiac arrhythmia (2699 [27%]), renal failure (2287 [23%]), heart failure (1963 [20%]), and chronic pulmonary disease (1358 [14%]). Dialysis was required in 599 (6%) of all patients and in 469 (27%) of 1727 ventilated patients. The Charlson comorbidity index was 0 for 3237 (39%) of 8294 patients without ventilation, but only 374 (22%) of 1727 ventilated patients. The mean duration of ventilation was 13·5 days (SD 12·1). In-hospital mortality was 22% overall (2229 of 10 021), with wide variation between patients without ventilation (1323 [16%] of 8294) and with ventilation (906 [53%] of 1727; 65 [45%] of 145 for non-invasive ventilation only, 70 [50%] of 141 for non-invasive ventilation failure, and 696 [53%] of 1318 for invasive mechanical ventilation). In-hospital mortality in ventilated patients requiring dialysis was 73% (342 of 469). In-hospital mortality for patients with ventilation by age ranged from 28% (117 of 422) in patients aged 18-59 years to 72% (280 of 388) in patients aged 80 years or older. INTERPRETATION: In the German health-care system, in which hospital capacities have not been overwhelmed by the COVID-19 pandemic, mortality has been high for patients receiving mechanical ventilation, particularly for patients aged 80 years or older and those requiring dialysis, and has been considerably lower for patients younger than 60 years. FUNDING: None.
引用
- Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020. PMID: 32735842. doi:10.1016/S2213-2600(20)30316-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。